ORGANIZATION

• Just Protecting Prices of On-Patent Meds Would Lead to 1.3% Growth in Japan: PhRMA
  April 24, 2023

• Asian Pharma Groups Adopt Position Paper to Push E-Labeling
  April 20, 2023

• Pharma CEOs Call for Japan’s Leadership to Tackle Global Health Issues at G7 Summit
  April 17, 2023

• Japan, US, EU Trade Groups Push Price Maintenance during Patent Period: Joint Statement
  April 17, 2023

• European Pharma CEOs Prod Japan to Rethink Drug Pricing System: Forum
  April 13, 2023

• Scrap Numerical Target for Generic Use: Gx/Biosimilar Association to Govt
  April 11, 2023

• Generic Use Rate Hits Record 81.2% in October-December: JGA
  April 7, 2023

• JCHO Bars 6 Wholesalers from Drug Procurement Bids in Kyushu
  March 30, 2023

• JOHAS Follows Suit to Suspend 6 Wholesalers from Future Bids
  March 29, 2023

• Six Wholesalers Barred from NHO Bids after FTC Confirms Bid-Rigging
  March 28, 2023

• Hight Time to Hold Fundamental Debate on Drug Price Revisions: FPMAJ Director General
  March 24, 2023

• Japan Umbrella Trade Organ to Beef Up Functions for Lobbying Activity
  March 24, 2023

• Over 20% of All Generics under Restricted Shipments: FPMAJ
  March 14, 2023

• PhRMA Unveils Proposal for FY2024 Reform, Says This Year Is “Turning Point” to Improve Access
  March 10, 2023

• Labor Unions Prod MHLW to Renew Efforts to Improve Compliance with Drug Distribution Guidelines
  March 3, 2023

• OB/GYN Group Urges MHLW to Facilitate Access to Oral Abortion Drug
  February 24, 2023

• Policy Veterans’ Group Floats Proposal to Prevent Unprofitability to Stabilize Drug Supply
  February 21, 2023

• JPMA Chief Calls for Prompt Price Cuts for LLPs, Generic Industry Consolidation
  February 17, 2023

• Japan Citizen’s Group Objects Pfizer’s Partnership with Tokyo Govt
  February 1, 2023

• PhRMA Poised to Issue 2024 Reform Proposal in Next Few Months: New Japan Chief
  January 25, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• …
• Next ›
• 最終 »